PLSE
Pulse Biosciences Inc

1,939
Mkt Cap
$965.69M
Volume
135,917.00
52W High
$25.00
52W Low
$12.56
PE Ratio
-12.55
PLSE Fundamentals
Price
$14.25
Prev Close
$14.10
Open
$14.07
50D MA
$14.17
Beta
1.33
Avg. Volume
183,834.05
EPS (Annual)
-$0.9176
P/B
10.41
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 1.4% - Here's What Happened
Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 1.4% - Here's Why...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced that...
Business Wire·12d ago
News Placeholder
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced plans...
Business Wire·20d ago
News Placeholder
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced that...
Business Wire·30d ago
News Placeholder
PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial
PLSE has secured FDA IDE approval to launch its nPulse AF ablation study.
Zacks·30d ago
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Trading Up 5% - Here's What Happened
Pulse Biosciences (NASDAQ:PLSE) Trading 5% Higher - Time to Buy...
MarketBeat·1mo ago
News Placeholder
PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor
Pulse Biosciences partners with MD Anderson to study its nPulse technology for treating benign and malignant thyroid tumors upon receiving FDA approval for a first-in-human trial.
Zacks·1mo ago
News Placeholder
Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse Technology
Pulse Biosciences, Inc. (Nasdaq: PLSE) (the Company or Pulse Biosciences), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or...
Business Wire·1mo ago
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Hits New 12-Month Low - Here's What Happened
Pulse Biosciences (NASDAQ:PLSE) Reaches New 12-Month Low - Time to Sell...
MarketBeat·2mo ago
News Placeholder
Pulse Biosciences is Now Oversold (PLSE)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...
Nasdaq News: Markets·2mo ago
<
1
2
...
>

Latest PLSE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.